Comparison of two assays for molecular determination of rifampin resistance in clinical samples from patients with Buruli ulcer disease.
This study evaluates a novel assay for detecting rifampin resistance in clinical Mycobacterium ulcerans isolates. Although highly susceptible for PCR inhibitors in 50% of the samples tested, the assay was 100% M. ulcerans specific and yielded >98% analyzable sequences with a lower limit of detection of 100 to 200 copies of the target sequence.
Department of Infectious Diseases and Tropical Medicine (DITM), University Hospital, Ludwig-Maximilians-University, Munich, Germany.
Moritz
M
Jansson
Marcus
M
Beissner
Richard Odame
RO
Phillips
Kossi
K
Badziklou
Ebekalisai
E
Piten
Issaka
I
Maman
Fred Stephen
FS
Sarfo
Kristina Lydia
KL
Huber
Agata
A
Rhomberg
Dominik
D
Symank
Magdalena
M
Wagner
Franz
F
Wiedemann
Jörg
J
Nitschke
Abiba
A
Banla Kere
Karl-Heinz
KH
Herbinger
Ohene
O
Adjei
Thomas
T
Löscher
Gisela
G
Bretzel
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D054312:Buruli Ulcer / Q000382:microbiology; D024881:Drug Resistance, Bacterial; D006801:Humans; D008826:Microbial Sensitivity Tests / Q000379:methods; D025202:Molecular Diagnostic Techniques / Q000379:methods*; D019911:Mycobacterium ulcerans / Q000187:drug effects* / Q000302:isolation & purification; D012293:Rifampin / Q000494:pharmacology*; D012680:Sensitivity and Specificity
D000900:Anti-Bacterial Agents; D012293:Rifampin